Viron Therapeutics, Inc.
🇨🇦Canada
- Country
- 🇨🇦Canada
- Ownership
- Holding
- Established
- 1997-01-01
- Employees
- -
- Market Cap
- -
- Website
- http://www.vironinc.com
Clinical Trials
2
Active:0
Completed:0
Trial Phases
2 Phases
Phase 1:1
Phase 2:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Phase 1
1 (50.0%)Phase 2
1 (50.0%)Treatment of Elderly Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic (MD) Syndrome With Laromustine and Infusional Cytarabine
Phase 1
Terminated
- Conditions
- Acute Myeloid Leukemia (AML)Myelodysplastic Syndrome (MDS)
- Interventions
- First Posted Date
- 2008-04-09
- Last Posted Date
- 2019-01-28
- Lead Sponsor
- Viron Therapeutics Inc
- Target Recruit Count
- 25
- Registration Number
- NCT00655395
- Locations
- 🇺🇸
Weill Cornell Medical College, New York, New York, United States
Serp-1 for the Treatment of Acute Coronary Syndrome
Phase 2
Terminated
- Conditions
- Unstable AnginaCoronary AtherosclerosisCoronary Restenosis
- First Posted Date
- 2005-10-21
- Last Posted Date
- 2009-02-06
- Lead Sponsor
- Viron Therapeutics Inc
- Target Recruit Count
- 72
- Registration Number
- NCT00243308
- Locations
- 🇺🇸
Washington Hospital Center, Washington, District of Columbia, United States
🇺🇸University of Florida, Gainesville, Florida, United States
🇺🇸Spectrum Health, Grand Rapids, Michigan, United States
News
No news found